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Background: To date, no guideline is proposed for elderly nasopharyngeal carcinoma (NPC) due to lack of prospective
clinical trials. The present study comparing the survivals and toxicities in elderly NPC patients received either induction
chemotherapy followed by radiotherapy(IC + RT) or concurrent chemoradiotherapy (CCRT) was therefore undertaken to
provide a more accurate basis for future clinical practice.
Methods: The eligible elderly NPC patients were retrospectively enrolled. Propensity score matching generated a
matched cohort (1:2) composed from CCRT and IC + RT groups. The survivals and treatment-induced toxicities were
compared between two groups. Multivariable analysis was carried to identify significant prognostic factors.
Results: The 5-year overall survival, cancer-specific survival, locoregional failure-free survival, distant failure-free survival
for all patients were 58.3 %, 62.7 %, 88.7 %, 83.0 %, respectively. No significant survival differences were found
between CCRT and IC + RT groups in the propensity-matched cohort. In comparison with the patients who
received IC + RT, patients who underwent CCRT were associated with more severe acute toxicities including
leucopenia (30 % vs. 6.8 %, P = 0.005), anemia (20 % vs. 4.1 %, P = 0.027), mucositis (63.3 % vs. 34.2 %, P = 0.007),
weight loss (23.4 % vs. 4.1 %, P = 0.009). Basicranial bone involvement was an independent prognostic factor
that predicted all-cause death (HR = 0.553, 95 % CI 0.329–0.929; P = 0.025) and cancer specific death (HR = 0.558,
95 % CI 0.321–0.969; P = 0.038) in elderly patients.
Conclusions: In the context of no guideline for elderly NPC, the present study suggested IC + RT should be a
preferable modality compared with CCRT, with similar treatment outcomes but less acute toxicities.
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Nasopharyngeal carcinoma (NPC) is a special head and
neck cancer in terms of its epidemiology, etiology, clinical
presentation, and prognostic factors [1]. The incidence of
NPC is increasing with age in the endemic areas, with a
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risk population [2]. Elderly NPC patients (age ≥ 60 years)
constitutes about 13.8 % (1310/9527) of all NPC [3, 4]. To
date, the treatment for geriatric NPC patients generally
follows guidelines tailored for non-elderly patients, but
the elderly are usually excluded from prospective clinical
trials because of restrictive selection criteria. The develop-
ment of prospective trials for elderly patients has been
hindered by the rarity of patients and accrual difficulties
due to the prevalence of comorbidities and decreasing
organ function in elderly patients. When a prospectivele is distributed under the terms of the Creative Commons Attribution 4.0
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spective study is of paramount importance in the light of
evidence that NPC has certain distinctive characteristics
when it occurs in elderly patients [4].
A retrospectively matched cohort study [3] of chemo-
radiotherapy versus radiotherapy alone in elderly NPC
patients from our institute was published in January
2015. In this study, patients received combined chemo-
radiotherapy, which defined as induction chemotherapy
followed by radiotherapy(IC + RT) or concurrent chemora-
diotherapy(CCRT), have presented significantly better sur-
vival compared with patients received RT alone. Moreover,
a 2013 matched analysis also showed CCRT significantly
improved the survival in elderly NPC [5]. Thus, we were in-
terested to determine which treatment modality (IC + RT
or CCRT) was the optimal treatment strategy for elderly
NPC patients. According to previous studies in non-elderly
patients [6, 7], we hypothesized that no significant differ-
ence of survival will be observed between IC + RT and
CCRT groups in elderly patients, but more severe
treatment-induced toxicities in CCRT group. If our hypoth-
esis is correct, we propose sequential chemoradiotherapy
(IC + RT) should be recommended for elderly NPC patients
in view of poorer tolerance to CCRT in elderly patients as
opposed to younger ones.
This present study was therefore undertaken to compare
the survivals and treatment-induced toxicities between
IC + RT and CCRT groups using a propensity-matched
analysis in elderly NPC patients (age ≥ 60 years).
Methods
From January 1998 and December 2003, the patients
selected consecutively in our institute met the following
criteria: (i) biopsy-proven, previously untreated WHO II
or III NPC ; (ii) elderly patient who is 60 years or older;
(iii) no second primary tumors; (iv) patients without sys-
temic metastasis; (v) patients received definitive radiother-
apy. The study was approved by the Clinical Research
Ethics Committee of Sun Yat-sen University Cancer Center.
It was a retrospective analysis of routine data and thus we
were granted a waiver of individual informed consent. All
patients were evaluated by the following examinations
before treatment: complete patient history, physical exam-
ination, CT or MRI of the neck and nasopharynx, chest
radiography, abdominal ultrasonography, and acquisition of
whole body bone scans by single photon emission com-
puted tomography (ECT). All patients were restaged ac-
cording to the sixth edition AJCC/UICC staging system.
Radiotherapy
All patients received external beam RT by conventional
fractionation; Details of RT technique in our cancer center
have been reported previously [3]. To put it simply,
64–72 Gy (in 6.5–7 weeks) were delivered to theprimary tumor, 60–66 Gy to clinically involved nodes,
and 48–50 Gy to uninvolved cervical and supraclavi-
cular areas. Patients with involvement of the skull base
were delivered a booster dose (8 to 10 Gy per four to
five fractions).
Chemotherapy
The induction or adjuvant chemotherapy (AC) regimen
was mainly a combination of cisplatin and 5-fluorouracil
(5-Fu), with cisplatin (30 mg intravenously) given on
Day 1–5 and 5-fluorouracil (750 mg intravenously) on
Days 1–5, repeated every 3 weeks. The concurrent
chemotherapy regimen was mainly cisplatin alone, with
cisplatin (30–40 mg/m2 on Day 1) given intravenously
weekly or cisplatin (80–100 mg/m2) given intravenously
3-weekly. Dose modification was applied, if needed, at
doctor’s discretion.
Patient assessment and follow-up
After treatment, patients were assessed every 3 months
by the first 3 years, and every 6 months thereafter until
the fifth year. The local recurrences were diagnosed on
MRI or CT scanning or by fiber optic endoscopy and bi-
opsy. Regional recurrences were diagnosed by physical
examination or MRI/intensive CT scans; irresolute cases
were confirmed by fine-needle aspiration. Distant metas-
tases were diagnosed by combined modalities including
CT or MR, bone scan, abdominal ultrasonography, and
chest x-ray. Chemotherapy-related toxicities were graded
according to the Common Terminology Criteria for
Adverse Events (CTCAE) v4.0 [8]. Acute and late RT-
related toxicities were graded using the Radiation
Morbidity Scoring Criteria of the Radiation Therapy
Oncology Group [9]. Late toxicities referred to symp-
toms that occurred or continued beyond 90 days since
the commencement of RT.
Statistical analysis
The primary end points were overall survival (OS),
cancer-specific survival (CSS). The secondary end points
were local-regional failure-free survival (LR-FFS), and
distant failure-free survival (D-FFS). All intervals were
calculated from the date of beginning therapy. OS was
defined as the time until death from any causes. CSS
referred to the time until death from NPC. LR-FFS was
defined as the time until the first recurrence in the cer-
vical and/or nasopharyngeal region after radiotherapy.
D-FFS was defined as the time until distant metastasis.
Baseline characteristics of patients in the two groups
were accessed using descriptive statistics. The statistical
results were presented as the mean ± standard deviation
or percentages. Given the differences in the baseline
characteristics between the two groups, propensity-score
matching was used to identify the cohort of patients
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formed with the use of a 1:2 matching protocol (nearest-
neighbor) for CCRT and IC + RT groups. The matching
covariates consisted of age, gender, T classification, N
classification, RT dose to nasopharynx and involved cervical
lymph node, RT time, cranial nerve involvement, basi-
cranial bone involvement, and family history. Survival
analysis was carried out using the Kaplan–Meier method
and compared with the log-rank test. The median follow-
up time was calculated using the reverse KM estimator
[10]. Univariate analyses with the unadjusted Cox propor-
tional hazards model were performed to calculate the
hazard ratio (HR). Multivariate analyses using the Cox
proportional hazards model were performed to identify in-
dependent prognostic factors through the backward elimin-
ation. A two-sided P-value of less than 0.05 was taken as
statistically significant. The statistical analyses were
performed using SPSS version 19.0 (SPSS, Inc., an IBM
Company; Chicago, IL, USA). In addition, the propensity-
matched analysis was performed using the MatchIt package
[11] in R Statistical Software (version 3.1.3; R Foundation
for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics, survival and patterns of
treatment failure in the entire patient
Between January 1998 and December 2003, a total of
498 eligible elderly patients were included in this present
study, with a median age of 65 years (60–84 years). The
ratio of male to female was 4.53:1, with 408 males and
90 females. The clinical stage distribution was: stage I,
23 (4.6 %); stage II, 127 (25.5 %); stage III, 185 (37.1 %),
and stage IVa 163 (32.7 %). In total, 171 (34.3 %) patients
were treated with combined chemo-radiotherapy (CRT)
and 327 (65.7 %) received radiotherapy (RT) alone. The
reverse KM estimate of the median follow-up was
64.7 months (95 % CI: 62.87–66.52 months). The me-
dian OS time was 74.6 months. 46 (9.2 %) patients de-
veloped locoregional relapse, 78 (15.7 %) developed
distant metastases, and 212 (42.6 %) died. The 1-, 3- and
5-year survival rates for the entire group were as follows:
OS, 99.8 %, 70.2 % and 58.3 %; CSS, 99.8 % , 72.5 % and
62.7 %; LR-FFS, 99.6 %, 91.5 % and 88.7 %; and D-FFS,
99.8 % , 85.4 % and 83.0 %.
Treatment Exposure
One hundred seventy-one patients received combined
chemo-radiotherapy. In which, 111 cases received IC,
only 73 cases completed a full course of two cycles of
IC; 44 cases received CCRT, only 30 cases completed 3-
weekly concurrent regimens for three cycles or weekly
CCRT for at least five cycles; 15 cases received IC +
CCRT/AC, only 13 cases completed at least three cycles.
Additionally, just 1 case received one cycle of AC. Ananalysis of IC delivery found patients received fixed lower
total doses of each chemotherapeutic drug irrespective of
body surface area, primarily as a result of arbitrary dose
modification of chemotherapy owing to fear of excessive
side-effects. With respect of CCRT, 22.7 % (10/44) pa-
tients received decreased doses of cisplatin. The mean
total dose of cisplatin was 249 mg vs. 200 mg (p = 0.046)
between patients received IC + RT and patients received
CCRT. These results showed patients received higher dose
of cisplatin in the IC + RT group.Baseline characteristics between IC + RT and CCRT groups
The baseline characteristics between IC + RT and CCRT
groups showed in Table 1. Before propensity-score match-
ing, there were no significant differences between the two
groups regarding the age, gender, T classification, naso-
pharynx dose, lymph node dose, RT days, basicranial
bone involvement and family history. Compared with
the CCRT group, the IC + RT group had significantly
more patients developed cranial nerve involvement
(20.7 % VS. 6.8 %, P = 0.037), showed significantly more
advanced clinical stage (54.1 % VS. 40.9 %, P = 0.048),
and N classification (20.7 % VS. 4.5 %, P = 0.018). With
the use of propensity-score matching (1:2), 44 patients
who underwent CCRT were matched with 88 patients
who underwent IC + RT. After matching, the balance
improvement of the mean differences for all variables
were 29.8 %, and baseline characteristics between the
two groups were well balanced (Table 1).Survival in the propensity score-matched cohort
As shown in Fig. 1, The 5-year OS for the IC + RT and
CCRT groups were 62.1 % and 52.3 % (P = 0.218, Fig. 1a),
respectively. The 5-year CSS rate in the IC + RT group
was 65.2 % compared with 55.7 % in the CCRT group
(P = 0.180, Fig. 1b). The 5-year LR-FFS for the IC + RT
and CCRT groups were 88.2 % and 85.3 % (P = 0.607,
Fig. 1c), respectively. The 5-year D-FFS rate in the IC +
RT group was 75.3 % compared with 81.8 % in the
CCRT group (P = 0.239, Fig. 1d). These results showed
no significant differences were found between the two
groups in OS, FFS, LR-FFS, or D-FFS.
To further clarify the role of IC and CCRT in
NPC, Patients received sufficient cycles of IC (n =
73) and CCRT (n = 30) were compared using the
propensity score matching. Similarly, baseline char-
acteristics were well matched after propensity score
matching (Additional file 1: Table S1). Still, no sur-
vival benefits were observed between IC + RT and
CCRT groups for 5-year OS (65.6 % VS. 57.0 %, P =
0.332), CSS (66.7 % VS. 59.1 %, P = 0.332), LR-FFS
(88.4 % VS. 84.3 %, P = 0.545), and D-FFS (81.6 %
VS. 71.9 %, P = 0.952).
Table 1 Baseline characteristics before and after propensity-score matching between IC + RT and CCRT groups
Characteristics Before Matching P After Matching P
IC + RT(N = 111) CCRT(N = 44) IC + RT(N = 88) CCRT(N = 44)
Age (y) 0.900 0.506
Mean 64.09 64.59 64.16 64.59
SD 3.20 4.06 3.20 4.06
Gender (%) 0.059 1.000
Male 95(85.6) 38(86.4) 76(86.4) 38(86.4)
Female 16(14.4) 6(13.6) 12(13.6) 6(13.6)
T-stage (%) 0.817 0.404
T1 4(3.6) 1(2.3) 4(4.5) 1(2.3)
T2 21(18.9) 11(25.0) 16(18.2) 11(25.0)
T3 44(39.6) 16(36.4) 36(40.9) 16(36.4)
T4 42(37.8) 16(36.4) 32(36.4) 16(36.4)
N-stage (%) 0.018 0.068
N0 19(17.1) 11(25) 18(20.5) 11(25)
N1 24(21.6) 17(38.6) 20(22.7) 17(38.6)
N2 45(40.5) 14(31.8) 40(45.5) 14(31.8)
N3 23(20.7) 2(4.5) 10(11.4) 2(4.5)
Clinical stage (%) 0.048 0.175
II 4(3.6) 6(13.6) 4(4.5) 6(13.6)
III 47(42.3) 20(45.5) 43(48.9) 20(45.5)
IV 60(54.1) 18(40.9) 41(46.6) 18(40.9)
NP dose (Gy) 0.725 0.704
Mean 71.03 71.23 71.00 71.23
SD 3.07 3.48 3.11 3.48
LN dose (Gy) 0.054 0.230
Mean 61.87 59.83 61.21 59.83
SD 5.79 6.26 6.13 6.26
RT days 0.390 0.428
Mean 45.16 47.25 48.53 47.25
SD 8.79 8.32 8.95 8.32
CNI (%) 0.037 0.245
Present 23(20.7) 3(6.8) 12(13.6) 3(6.8)
Absent 88(79.3) 41(93.2) 76(86.4) 41(93.2)
BBI (%) 0.387 0.458
Present 47(42.3) 22(50.0) 38(43.2) 22(50.0)
Absent 64(57.7) 22(50.0) 50(56.8) 22(50.0)
Family history (%) 0.632 0.907
Present 6(5.4) 4(9.1) 6(6.8) 4(9.1)
Absent 105(94.6) 40(90.9) 82(93.2) 40(90.9)
IC + RT induction chemotherapy followed by radiotherapy, CCRT concurrent chemoradiotherapy, NP nasopharynx, LN lymph node, CNI Cranial nerve involvement,
BBI Basicranial Bone involvement, SD standard deviation
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score-matched cohort
As shown in Table 2, in the univariate analysis, treatment
group(IC + RT vs. CCRT) was not associated with survival;basicranial bone involvement was significant factor that
predicted OS (HR = 0.553; 95 % CI 0.329–0.929; P = 0.025)
and CSS (HR = 0.558; 95 % CI 0.321–0.969; P = 0.038).
After adjustment for age (continuous variable), gender
Fig. 1 Kaplan-Meier survival curves for the IC + RT and CCRT groups. Notes: Overall survival (a), Cancer-specific survival (b), Locoregional failure-free
survival (c), and distant failure-free survival (d); Hazard ratios (HRs) were calculated with the unadjusted Cox proportional hazards model; P values were
calculated with the unadjusted log-rank test. CCRT:concurrent chemoradiotherapy; IC + RT: induction chemotherapy followed by radiotherapy alone.
The supplementary dataset file shows the data used in our study, including age group, family history, VCA/EA-IgA, clinical stage, T stage, N stage, RT
dose, cranial nerve involvement, basicranial bone involvement, treatment group
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classification (N0-1 vs. N2-3), clinical stage (I-II vs. III-IV),
nasopharynx dose (continuous variable), lymph node dose
(continuous variable), cranial nerve involvement(absent vs.
present), basicranial bone involvement(absent vs. present)and family history(absent vs. present), treatment
group(IC + RT vs. CCRT) still failed to predict OS
(HR = 0.706; 95 % CI 0.412–1.208; P = 0.204), CSS
(HR = 0.708; 95 % CI 0.402–1.246; P = 0.231), LR-
FFS(HR = 0.696; 95 % CI 0.207–2.342; P = 0.558), and
Table 2 Univariate and multivariate analyses in patients received IC + RT(n = 88) or CCRT(n = 44) after propensity score matching
OS CSS LRFFS DFFS
HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P HR (95 % CI) P
Univeriate parameter
Age Continuous variable 1.051(0.977–1.131) 0.185 1.046 (0.967–1.132) 0.261 0.892(0.737–1.079) 0.239 1.044(0.945–1.154) 0.399
Gender male vs. female 1.301(0.590–2.869) 0.514 1.119(0.504–2.487) 0.782 2.131(0.277–16.397) 0.467 1.434(0.433–4.751) 0.555
T-stage T1-2 vs. T3-4 0.907(0.496–1.659) 0.752 0.974(0.518–1.833) 0.936 2.725(0.915–8.115) 0.072 0.984(0.418–2.320) 0.971
N-stage N0-1vs. N2-3 0.902(0.538–1.512) 0.902 1.087(0.628–1.883) 0.765 1.200(0.403–3.570) 0.744 0.763(0.361–1.614) 0.479
Clinical stage I-II vs. III-IV 0.805(0.291–2.228) 0.805 0.929(0.334–2.580) 0.887 2.088(0.462–9.430) 0.338 0.436(0.059–3.209) 0.415
NP dose (Gy) Continuous variable 1.007(0.930–1.090) 0.862 1.002(0.921–1.090) 0.960 0.925(0.808–1.058) 0.253 1.042(0.923–1.175) 0.510
LN dose (Gy) Continuous variable 1.023(0.980–1.068) 0.292 1.021(0.975–1.068) 0.380 0.946(0.871–1.027) 0.187 1.057(0.993–1.125) 0.083
RT Days Continuous variable 1.006(0.981–1.032) 0.623 1.010(0.984–1.037) 0.451 0.954(0.887–1.026) 0.203 1.013(0.977–1.050) 0.493
Treatment group IC + RT vs. CCRT 0.717(0.421–1.220) 0.220 0.682(0.388–1.198) 0.183 0.747(0.244–2.284) 0.609 1.709(0.693–4.218) 0.245
Cranial nerve involvement absent vs. present 0.781(0.354–1.726) 0.542 0.663(0.298–1.476) 0.314 0.581(0.128–2.628) 0.481 0.657(0.228–1.896) 0.437
Basicranial Bone involvement absent vs. present 0.553(0.329–0.929) 0.025 0.558(0.321–0.969) 0.038 0.784(0.263–2.341) 0.663 0.712(0.339–1.497) 0.371
Family history absent vs. present 1.142(0.413–3.155) 0.798 1.349(0.420–4.335) 0.615 22.74(0.003–25.96) 0.494 0.655(0.197–2.171) 0.489
Multivariate parametera
Treatment group IC + RT vs. CCRT 0.706(0.412–1.208) 0.204 0.708(0.402–1.246) 0.231 0.696(0.207–2.342) 0.558 1.627(0.658–4.023) 0.292
Basicranial Bone involvement absent vs. present 0.553(0.329–0.929) 0.025 0.558(0.321–0.969) 0.038 0.246(0.044–1.382) 0.111 0.760(0.337–1.715) 0.508
T-stage T1-2 vs. T3-4 1.347(0.638–2.842) 0.435 1.490(0.675–3.289) 0.324 6.833(1.224–38.148) 0.028 1.355(0.481–3.819) 0.565
CI confidence interval, IC + RT induction chemotherapy followed by radiotherapy, CCRT concurrent chemoradiotherapy, NP nasopharynx, LN lymph node
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The significant variable that predicted all-cause death
and cancer specific death was basicranial bone involvement.
Additionally, T classification was independent prognostic
factor that predicted localregional tumor recurrence.
Treatment toxicities
To compare the incidence of treatment toxicities
between IC + RT and CCRT groups, patients received
sufficient courses of IC + RT or CCRT were chose. As
listed in Table 3. Regarding hematologic toxicities, in-
cidences of grade III and IV leukopenia (30 % vs.
6.8 %, P = 0.005), anemia (20 % vs. 4.1 %, P = 0.027)
and granulocytopenia (26.7 % vs. 5.5 %, P = 0.007)
were significantly higher in the CCRT group. No
significant difference in thrombocytopenia (13.3 % vs.
2.7 %, P = 0.105) was found between the two groups.
With respect to nonhematologic toxicity, the incidences
of grade III and IV mucositis (63.3 % vs. 34.2 %, P =
0.007), skin reaction (20.0 % vs. 4.1 %, P = 0.027), and
weight loss (23.4 % vs. 4.1 %, P = 0.027) were significantly
higher in the CCRT group; while no significant differences
were detected regarding the incidence of severe vomiting
and hepatic impairment between the groups. In addition,
no severe renal toxicity was seen in either group. Late
toxicities were also analyzed in our study. Unlike acuteTable 3 Incidences of serious toxicities during radiotherapy
course between IC + RT and CCRT groups
Toxicity IC + RT (%,N = 73) CCRT (%,N = 30) P
Grade 3 Grade 4 Grade 3 Grade 4
Acute toxicity
Leukopenia 5(6.8) 0 7(23.3) 2(6.7) 0.005
Granulocytopenia 4(5.5) 0 6(20.0) 2(6.7) 0.007
Thrombocytopenia 2(2.7) 0 3(10.0) 1(3.3) 0.105
Anemia 2(2.7) 1(1.4) 4(13.3) 2(6.7) 0.027
Vomiting 0 0 2(6.7) 0 0.149
Mucositis 25(34.2) 0 16(53.3) 3(10.0) 0.007
Skin reaction 3(4.1) 0 5(16.7) 1(3.3) 0.027
Hepatic impairment 1(1.4) 0 1(3.3) 0 1.000
Renal impairment 0 0 0 0
Weight loss 3(4.1) 0 5(16.7) 2(6.7) 2(6.7)
Late toxicity
Xerostomia 3(4.1) 0 2(6.7) 0 0.965
Subcutaneous Fibrosis 5(6.8) 0 2(6.7) 0 1.000
Temporal lobe necrosis 2(2.7) 0 1(3.3) 0 1.000
Trismus 2(2.7) 0 0 0 0.897
Dysphagia 3(4.1) 0 2(6.7) 0 0.965
Cranial neuropathy 1(1.4) 0 0 0 1.000
IC + RT induction chemotherapy followed by radiotherapy, CCRT concurrent
chemoradiotherapytoxicities, the incidence of severe late toxicities was com-
parable between both groups (Table 3).
Discussion
Numerous studies were carried out to address the use of
chemotherapy in combination with RT for the care of
locoregionally advanced NPC (which involved only a few
elderly patients). A 2012 meta-analysis [12] which in-
cluded six trials in IC + RT group (n = 1418) and five in
AC group (n = 1187) found that IC + RT can effectively
enhance OS and reduce the risk of distant failure. How-
ever, a recent another meta-analysis [13] that included
19 trials and 4806 patients confirmed the addition of
chemotherapy to radiotherapy significantly improved OS
in favor of CCRT + AC and CCRT without AC but not
AC alone or IC + RT alone. To date, it is generally
believed that CCRT is the most efficacious modality for
non-elderly patients. In contrast, previous studies for
elderly NPC patients have shown either IC + RT or CCRT
can improve the survival of elderly NPC patients [3, 5].
But which is a favorable regimen remains unclear, it is
necessary to elucidate the roles of IC + RT or CCRT in
elderly NPC patients given the poor compliance with
combined chemoradiotherapy, especially CCRT.
In the present propensity-matched study, the results
confirmed our hypothesis. No significant differences
between IC + RT and CCRT groups were found regard-
ing overall survival, cancer-specific survival, locoregional
failure-free survival, or distant failure-free survival. Pa-
tients received sufficient cycles of IC (n = 73) and CCRT
(n = 30) were further compared using the propensity-
matched analysis. We found that 5-year OS, CSS,and D-
FFS were higher in the IC + RT group compared with
CCRT group, but the difference was not statistical signif-
icance(OS:65.6 % VS. 57.0 %, P = 0.332; CSS: 65.6 % VS.
57.0 %, P = 0.332; D-FFS: 81.6 % VS. 71.9 %, P = 0.952).
This was mainly due to the relatively small matched
pairs even using 1:2 matching on the propensity score
(Additional file 1: Table S1).
The most probable explanation for this negative result
might either IC + RT or CCRT can improve the locoreginal
control, but failed to further decrease the distant metastasis
compared with radiotherapy alone. NPC is a highly chemo-
sensitive solid tumor [14]. Induction chemotherapy can in-
crease tumor sensitivity to radiation through shrinking the
primary tumor and improving the intratumoral blood
supply and re-oxygenation, which also lead to an increased
safety margin between the radiation volume and the tumor
volume [15, 16]; For patients received CCRT, the synergistic
effects between cytotoxic agents and radiation can also im-
prove the locoreginal control of the primary tumor [17].
Thus, the radiosensitizing effect of chemotherapy is similar
in patients received IC + RT or CCRT. However, neither
IC + RT nor CCRT can further improve the D-FFS in
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patients have worse compliance with combined chemora-
diotherapy compared to the non-elderly patients [3, 5]. In
addition, the effective of chemotherapy is involved with
dose intensity, but our data showed that elderly NPC
patients often received fixed lower total doses of each drug
irrespective of body surface area, mainly as a result of
arbitrary dose modification of chemotherapy owing to fear
of excessive side-effects, which was also seen in the other
studies [18, 19]. In clinical practice, because there were no
proposed guidelines for elderly NPC patients, oncologists
often attached importance to the treatment-related toxic-
ities and preferred a lower dose without evaluation. As a
consequence, this conservative treatment selection poten-
tially prevented some elderly patients from longer survival
[5]. More importantly, distant metastases remain the
predominant pattern of treatment failure in NPC patients
[20], previous studies have shown even IC +CCRT failed to
decrease the distant metastases [6, 7]. Geriatric oncologists
should exploit other advances made in the management of
non-elderly NPC, such as the addition of targeted agents to
chemoradiotherapy [21, 22], which have obtained some
promising outcomes (2-year D-FFS of about 90 %).
It is generally accepted that the elderly cancer patients
experienced an increased treatment-induced toxicity
[19, 23]. Some reasons accounting for this included
more common comorbidities [24], an increased exposure
to a drug (e.g. by impaired renal function or by prolonged
half-life due to decreased elimination) and changes in
pharmacodynamics caused by increased vulnerability of
organs with age [25]. However, previous studies shown
the rates of severe acute and late toxicities caused by
CCRT in elderly patients were similar with younger pa-
tients [5, 26]. It is likely that a selection and referral bias
in these studies lead to accrual of only fit elderly patients
[25]. In the present study, the toxicities in elderly patients
received sufficient courses of IC + RT or CCRT were com-
pared. Although the incidence of severe late toxicities was
comparable between both groups, patients received CCRT
were associated with more acute toxicities, as compared
with patients received IC + RT, including leucopenia, gran-
ulocytopenia, anemia, mucositis, skin reaction, weight loss
(Table 3). The high incidence of severe acute toxicities in
CCRT group may interrupt oncologic treatment, increase
the risk of unplanned hospitalization, and seriously affect
the quality of life in elderly patients [27, 28]. Thus, geriat-
ric oncologists should pay more attention to elderly NPC
patients received CCRT in future.
In spite of no significant survival differences between
CCRT and IC + RT groups, the entire patient cohort was
analyzed to identify valuable prognostic factors in the
elderly NPC patients. Multivariate analysis showed basicra-
nial bone involvement remained an independent prognostic
factor that predicted all-cause death and cancer specificdeath in elderly patients and Tclassification predicted local-
regional tumor recurrence. Contrary to several non-elderly
series [29–31], age, gender, N classification, and family
history failed to predict all survival endpoints for elderly
patients. The results suggested the potentially different
clinical characteristics between the elderly patients and
their younger ones.
To the best of our knowledge, there is very little
published information regarding the optimal chemotherapy
modalities of elderly NPC. In the past, the elderly NPC
patients were treated very differently at different cancer
centers. Our intention was not to test a novel therapy
but to ensure an equivalent therapeutic effect and less
treatment-induced toxicities for the elderly patients.
Some limitations in our study should be considered.
Firstly, this was a nonrandomized, retrospective study
and hence suffered from potential selection bias despite
robust propensity-score matching. Secondly, comorbidities
were not further assessed, which may have effect on sur-
vival, although cancer-specific survival was used to exclude
death due to comorbidities. Finally, all patients were treated
using conventional RT technique, whether it is preferable
to combine chemotherapy and intensity-Modulated
Radiation Therapy (IMRT) should be investigated in future.
Conclusions
In summary, the present propensity-matched study demon-
strated the elderly NPC patients received IC + RT achieve
similar survival outcomes compared with patients received
CCRT, but with less treatment-induced acute toxicities. In
the context of no guideline for elderly NPC, the present
study suggested IC + RT should be a preferable modality
compared with CCRT. It is hoped that the current out-
comes could provide a more accurate basis for designing
future clinical trials.
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